Agreement with Bill & Melinda Gates Medical Research Institute to
Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research
GAITHERSBURG, Md., June 5, 2023 /PRNewswire/
-- Novavax, Inc. (Nasdaq: NVAX), a global company advancing
protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a
three-year agreement with the Bill & Melinda Gates Medical Research
Institute to provide its adjuvant for use in preclinical vaccine research.
are excited to partner with the Bill & Melinda Gates Medical
Research Institute to include our unique technology in their public
health-focused vaccine research efforts," said John C. Jacobs,
President and Chief Executive Officer, Novavax. "Our Matrix-M™ adjuvant
is proven to enhance and broaden the immune system response when
included in vaccines and is already a key component of COVID and malaria
vaccines on the market today. We look forward to partnering more
broadly with a variety of organizations so that our technology can
benefit vaccine development across many disease areas."
Bill & Melinda Gates Medical Research Institute is committed to
developing biomedical interventions that address global health concerns
for those in the greatest need," said Emilio Emini, PhD,
chief executive officer of the Bill & Melinda Gates Medical Research
Institute. "We look forward to working with Novavax's Matrix-M™
adjuvant in some of our early-stage vaccine programs."
Matrix-M adjuvant is a key component of Novavax's COVID vaccine and its
development-stage vaccines including influenza and COVID and influenza
combined. In addition, the adjuvant is being used through partnerships
in clinical and preclinical programs across the world for the
development of both human and animal vaccines.
About Matrix-M™ AdjuvantWhen
added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant
enhances the immune system response, making it broader, and more
durable. The Matrix-M adjuvant stimulates the entry of
antigen-presenting cells at the injection site and enhances antigen
presentation in local lymph nodes.
Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing
and commercializing innovative vaccines to protect against serious
infectious diseases. Novavax, a global company based in Gaithersburg, Md.,
U.S., offers a differentiated vaccine platform that combines a
recombinant protein approach, innovative nanoparticle technology and
Novavax's patented Matrix-M adjuvant to enhance the immune response.
Focused on the world's most urgent health challenges, Novavax is
currently evaluating vaccines for COVID, influenza, and COVID and
influenza combined. Please visit novavax.com and LinkedIn for more information.Forward-Looking Statements